Stock HXL HEXIMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:10 2024-04-22 am EDT 		5-day change 1st Jan Change
0.013 AUD 0.00% Intraday chart for Hexima Limited 0.00% -27.78%
Mar. 22 Hexima Secures R&D Tax Rebate for Fiscal Year 2023 MT
Mar. 19 Hexima Changes Address MT

Valuation

Fiscal Period: June 2021 2022 2023
Capitalization 1 22.25 5.011 3.508
Enterprise Value (EV) 1 18.86 1.054 1.318
P/E ratio -2.77 x -0.46 x -1.83 x
Yield - - -
Capitalization / Revenue 5.45 x 0.86 x 2.36 x
EV / Revenue 4.62 x 0.18 x 0.89 x
EV / EBITDA -2.79 x -0.11 x -0.68 x
EV / FCF -3.82 x -0.18 x -1.11 x
FCF Yield -26.2% -559% -89.8%
Price to Book 7.3 x 1.1 x 1.26 x
Nbr of stocks (in thousands) 130,858 167,040 167,040
Reference price 2 0.1700 0.0300 0.0210
Announcement Date 8/27/21 9/30/22 8/31/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 4.372 3.432 2.568 4.082 5.811 1.485
EBITDA 1 -1.664 -2.742 -3.372 -6.759 -9.763 -1.945
EBIT 1 -1.846 -2.915 -3.534 -6.907 -9.905 -1.957
Operating Margin -42.23% -84.94% -137.61% -169.21% -170.46% -131.8%
Earnings before Tax (EBT) 1 -1.873 -2.891 -3.626 -6.874 -10.02 -1.919
Net income 1 -1.951 -2.896 -3.626 -6.874 -10.02 -1.919
Net margin -44.63% -84.38% -141.17% -168.39% -172.45% -129.24%
EPS 2 -0.0300 -0.0445 -0.0557 -0.0614 -0.0656 -0.0115
Free Cash Flow 1 -1.447 -0.5367 -0.7079 -4.932 -5.891 -1.184
FCF margin -33.09% -15.64% -27.56% -120.83% -101.39% -79.73%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/21/18 9/18/19 10/6/20 8/27/21 9/30/22 8/31/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 1.66 - - -
Net Cash position 1 1.92 0.35 - 3.39 3.96 2.19
Leverage (Debt/EBITDA) - - -0.4937 x - - -
Free Cash Flow 1 -1.45 -0.54 -0.71 -4.93 -5.89 -1.18
ROE (net income / shareholders' equity) -35.5% -90.7% -3,661% -965% -263% -52.2%
ROA (Net income/ Total Assets) -15.5% -29.5% -41.4% -64% -64.1% -17.8%
Assets 1 12.6 9.808 8.762 10.75 15.64 10.76
Book Value Per Share 2 0.0700 0.0300 -0.0200 0.0200 0.0300 0.0200
Cash Flow per Share 2 0.0300 0.0300 0.0200 0.0300 0.0200 0.0100
Capex 1 0.01 0 0 0 0 -
Capex / Sales 0.14% 0.03% 0.07% 0.06% 0.06% -
Announcement Date 8/21/18 9/18/19 10/6/20 8/27/21 9/30/22 8/31/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HEXIMA LIMITED Stock Hexima Limited
-27.78% 1.42M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HXL Stock
  4. Financials Hexima Limited